Comparative immunogenicity of recombinant B domain-deleted porcine factor VIII and Hyate:C in hemophilia A mice presensitized to human factor VIII
Open Access
- 1 April 2004
- journal article
- research article
- Published by Elsevier BV in Journal of Thrombosis and Haemostasis
- Vol. 2 (4), 605-611
- https://doi.org/10.1111/j.1538-7836.2004.00685.x
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Single Cell Analysis of Factor VIII-specific T Cells in Hemophilic Mice after Treatment with Human Factor VIIIThrombosis and Haemostasis, 2002
- Blockade of CD40/CD40 Ligand Interactions Prevents Induction of Factor VIII Inhibitors in Hemophilic Mice but Does not Induce Lasting Immune ToleranceThrombosis and Haemostasis, 2001
- Role of CD154 in the secondary immune response: the reduction of pre-existing splenic germinal centers and anti-factor VIII inhibitor titerEuropean Journal of Immunology, 2000
- Investigation of porcine parvovirus among persons with hemophilia receiving Hyate:C porcine factor VIII concentrateTransfusion, 2000
- Prevention and treatment of factor VIII inhibitors in murine hemophilia ABlood, 2000
- High incidence of anti‐FVIII antibodies against non‐coagulant epitopes in haemophilia A patients: a possible role for the half‐life of transfused FVIIIBritish Journal of Haematology, 1996
- Targeted disruption of the mouse factor VIII gene produces a model of haemophilia ANature Genetics, 1995
- Recombinant Factor VIII for the Treatment of Previously Untreated Patients with Hemophilia A -- Safety, Efficacy, and Development of InhibitorsNew England Journal of Medicine, 1993
- Gross Composition and Plasma and Extracellular Water Volumes of Tissues of a Reference MouseHealth Physics, 1992
- The Use of Porcine Factor VIII Concentrate (Hyate:C) in the Treatment of Patients With Inhibitor Antibodies to Factor VIIIArchives of Internal Medicine, 1989